Select a Sector or Industry
Drug Manufacturers - Major Stock Rankings
-
Accounts Payable
-
Accounts Receivable
-
Accruals
Pro
-
Altman Z-Score
Pro
-
Asset Utilization
-
Beneish M-Score
Pro
-
Book Value
-
Book Value per Share
-
Capital Expenditures
-
Cash Conversion Cycle
Pro
-
Cash Div. Payout Ratio TTM
Pro
-
Cash Financing
-
Cash Financing TTM
-
Cash Investing
-
Cash Investing TTM
-
Cash Operations
-
Cash Operations TTM
-
Cash and Equivalents
-
Cash and ST Investments
-
Current Ratio
-
Days Inventory Outstanding
Pro
-
Days Payable Outstanding
Pro
-
Days Sales Outstanding
Pro
-
Debt to Equity Ratio
-
Dividend Yield
-
EBITDA Margin TTM
Pro
-
EBITDA TTM
Pro
-
EV / EBIT
Pro
-
EV / EBITDA
Pro
-
EV / Free Cash Flow
Pro
-
EV / Revenues
Pro
-
Earnings Per Share
-
Earnings Per Share Growth
-
Earnings Per Share TTM
-
Earnings Yield
-
Effective Tax Rate TTM
Pro
-
Enterprise Value
-
Expenses
-
Expenses TTM
-
Free Cash Flow
-
Free Cash Flow TTM
-
Free Cash Flow Yield
Pro
-
Fundamental Score
Pro
-
Gross Profit Margin
-
Gross Profit TTM
-
Income from Cont. Ops
Pro
-
Interest Expense
-
Interest Income
-
Inventories
-
KZ Index
Pro
-
Liabilities
-
Long Term Debt
-
Market Cap
-
Net Income
-
Net Income TTM
-
Net PP&E
-
Operating Earnings Yield
Pro
-
Operating Margin TTM
Pro
-
Operating PE Ratio
Pro
-
Other Comprehensive Income
Pro
-
PE 10
Pro
-
PE Ratio
-
PE Value
Pro
-
PEG Ratio
-
PS Value
Pro
-
Payout Ratio TTM
Pro
-
Price
-
Price / Book Value
-
Price / Sales Ratio
-
Price / Tangible Book Value
Pro
-
Profit Margin
-
R&D Expense
-
Receivables Turnover
-
Retained Earnings
-
Retained Earnings Growth
-
Return on Assets
-
Return on Equity
-
Return on Invested Capital
Pro
-
Revenue Growth
-
Revenue Per Share TTM
-
Revenues
-
Revenues TTM
-
SG&A Expense
-
Shareholders Equity
-
Shares Outstanding
-
Stock Buybacks
-
Tangible Book Value
Pro
-
Tangible Book Value Per Share
Pro
-
Tangible Common Equity Ratio
Pro
-
Times Interest Earned TTM
Pro
-
Total Assets
-
Valuation (Historical Mult.)
Pro
-
Valuation Percentage
Pro
-
Value Score
Pro
Select from over 70 financial rankings
Or choose from these popular rankings:
Market Cap
View All
1
JNJ
Johnson & Johnson
169.61B
2
PFE
Pfizer
163.11B
3
NVS
Novartis
124.74B
4
MRK
Merck
113.18B
5
GSK
GlaxoSmithKline
109.65B
PE Ratio
View All
1
CPHI
China Pharma
0.8947
2
SKBI
Skystar Bio - Pharmaceutical Com...
1.226
3
AZN
AstraZeneca Group
6.147
4
SNY
Sanofi
10.35
5
LLY
Eli Lilly and Company
10.40
Dividend Yield
View All
1
AZN
AstraZeneca Group
9.70%
2
SNY
Sanofi
5.00%
2
GSK
GlaxoSmithKline
5.00%
4
LLY
Eli Lilly and Company
4.80%
4
NVS
Novartis
4.80%
Return on Equity
View All
1
GSK
GlaxoSmithKline
54.98%
2
AZN
AstraZeneca Group
37.69%
3
LLY
Eli Lilly and Company
30.04%
4
BMY
Bristol-Myers Squibb Company
23.72%
5
ABT
Abbott Laboratories
20.27%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Market Cap
View All| 1 | JNJ | Johnson & Johnson | 169.61B |
|---|---|---|---|
| 2 | PFE | Pfizer | 163.11B |
| 3 | NVS | Novartis | 124.74B |
| 4 | MRK | Merck | 113.18B |
| 5 | GSK | GlaxoSmithKline | 109.65B |
PE Ratio
View All| 1 | CPHI | China Pharma | 0.8947 |
|---|---|---|---|
| 2 | SKBI | Skystar Bio - Pharmaceutical Com... | 1.226 |
| 3 | AZN | AstraZeneca Group | 6.147 |
| 4 | SNY | Sanofi | 10.35 |
| 5 | LLY | Eli Lilly and Company | 10.40 |
Dividend Yield
View All| 1 | AZN | AstraZeneca Group | 9.70% |
|---|---|---|---|
| 2 | SNY | Sanofi | 5.00% |
| 2 | GSK | GlaxoSmithKline | 5.00% |
| 4 | LLY | Eli Lilly and Company | 4.80% |
| 4 | NVS | Novartis | 4.80% |
Return on Equity
View All| 1 | GSK | GlaxoSmithKline | 54.98% |
|---|---|---|---|
| 2 | AZN | AstraZeneca Group | 37.69% |
| 3 | LLY | Eli Lilly and Company | 30.04% |
| 4 | BMY | Bristol-Myers Squibb Company | 23.72% |
| 5 | ABT | Abbott Laboratories | 20.27% |